NCT00616772
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
See it on ClinicalTrials.gov ↗676 people
32.2%
67.8%
218 womenmiddle line = equal numbers458 men
- Phase
- PHASE3
- Paid for by
- AbbVie (prior sponsor, Abbott)
- Finished
- 2012-09
- Health conditions
- Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia
- Who could join
- Anyone
- Ages
- 45 Years – no maximum
- Average age
- mean 60.8 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnant or lactating women or women intending to become pregnant”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant or lactating women or women intending to become pregnant”
- No diabetes
Women with diabetes were turned away.
“Patients with diabetes mellitus that is poorly controlled”
Study titles and rules are shown in their original English.